ArticleFrontiers in medicine2025
A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to investigate patients with the three major types of primary glomerular diseases who underwent kidney biopsy at our center, with the objectives of characterizing their clinical phenotypes and pathological features, and identifying risk factors for clinical outcome events. Methods: Between January 2013 and December 2023, consecutive patients diagnosed with membranous nephropathy (MN), immunoglobulin A nephropathy (IgAN), and minimal change disease (MCD) by kidney biopsy were included in this retrospective follow-up study. Outcome measures included proteinuria remission and kidney disease progression events. Multivariate-adjusted Cox proportional hazards models were utilized. Results: A total of 608 patients were included in the follow-up cohort, comprising 438 with MN, 110 with IgAN, and 60 with MCD. Clinical remission was achieved in 481 (79.1%) patients, including 333 (54.8%) with complete remission (CR) and 148 (24.3%) with partial remission (PR). Kidney disease progression occurred in 79 (13.0%) patients. After balancing for baseline data and pathological diagnoses in relation to different outcomes, 24-h urinary total protein (24 h-UTP; ≥ 3.5 g/d vs. < 3.5 g/d: HR 1.35, 95% CI 1.10-1.64, Conclusion: Undertaken at a single center, this study outlines the spectrum of current treatments, clinical outcomes, and factors influencing these outcomes among patients newly diagnosed with the three principal glomerular diseases through kidney biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.